PAVmed Inc. (PAVM)

1,8800 -0,0200 (-1,05%) Börsenschluss: 04:00PM EDT

PAVmed Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917-813-1828
https://www.pavmed.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 107

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Lishan Aklog M.D.	Chairman & CEO	953,2k	N/A	1966
Mr. Dennis M. McGrath CPA	President & CFO	673,5k	N/A	1957
Mr. Shaun M. O'Neill M.B.A.	Executive VP & COO	498k	N/A	1983
Mr. Michael Adam Gordon	Executive VP, General Counsel & Secretary	710,5k	N/A	1975
Dr. Brian J. deGuzman M.D.	Executive VP, Chief Technology & Compliance Officer	427,6k	N/A	1965
Dr. Suman M. Verma M.D., Ph.D.	Senior VP of Molecular Genetics & Chief Scientific Officer	N/A	N/A	N/A
Michael Parks	Vice President of Investor Relations	N/A	N/A	N/A
Dr. Deepika A. Lakhani Ph.D.	Senior VP, Chief Regulatory & Quality Officer	N/A	N/A	N/A
Dr. Victoria T. Lee M.D.	Senior VP & Chief Medical Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Corporate Governance

PAVmed Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.